A mutant, noninhibitory plasminogen activator inhibitor type 1 decreases matrix accumulation in experimental glomerulonephritis

Journal of Clinical Investigation

Volumn 112, Issue 3, 2003, Pages 379-388

  Huang, Yufeng ^a   Haraguchi, Masashi ^a   Lawrence, Daniel A ^b   Border, Wayne A ^a   Yu, Ling ^a   Noble, Nancy A ^a,c  

^a UNIVERSITY OF UTAH   (United States)

^b HOLLAND LABORATORY   (United States)

^c Fibrosis Research Laboratory   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN; COLLAGEN TYPE 1; COLLAGEN TYPE 3; LAMININ; MESSENGER RNA; PLASMIN; PLASMINOGEN ACTIVATOR; PLASMINOGEN ACTIVATOR INHIBITOR 1; RECOMBINANT PLASMINOGEN ACTIVATOR; SCHIFF BASE; SCLEROPROTEIN; TRANSFORMING GROWTH FACTOR BETA; VITRONECTIN; ALLOANTIBODY; ANTI THY ANTIBODY; ANTI-THY ANTIBODY; FIBRONECTIN; RECOMBINANT PROTEIN; TGFB1 PROTEIN, HUMAN; TGFB1 PROTEIN, RAT; TRANSFORMING GROWTH FACTOR BETA1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL INFILTRATION; COMPETITIVE INHIBITION; CONTROLLED STUDY; DRUG ACTIVITY; DRUG EFFECT; DRUG MECHANISM; GLOMERULONEPHRITIS; GLOMERULOSCLEROSIS; HYPOTHESIS; IN VIVO STUDY; INFLAMMATORY CELL; MALE; MUTANT; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN METABOLISM; PROTEINURIA; RAT; STAINING; ANIMAL; BINDING COMPETITION; EXTRACELLULAR MATRIX; GENETICS; HUMAN; METABOLISM; MUTATION; PATHOLOGY; SPRAGUE DAWLEY RAT; TIME;

ANIMALS; BINDING, COMPETITIVE; EXTRACELLULAR MATRIX; FIBRONECTINS; GLOMERULONEPHRITIS; HUMANS; ISOANTIBODIES; MALE; MUTATION; PLASMINOGEN ACTIVATOR INHIBITOR 1; RATS; RATS, SPRAGUE-DAWLEY; RECOMBINANT PROTEINS; TIME FACTORS; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA1; VITRONECTIN;

EID: 0042388115     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI200318038     Document Type: Article

References (69)

1. Border, W.A., and Noble, N.A. 1994. Transforming growth factor beta in tissue fibrosis. N. Engl. J. Med. 331:1286-1292.
2. Border, W.A., Okuda, S., and Nakamura, T. 1989. Extracellular matrix and glomerular disease. Semin. Nephrol. 9:307-317.
3. Border, W.A., and Noble, N.A. 1998. Interactions of transforming growth factor-beta and angiotensin II in renal fibrosis. Hypertension. 31:181-188.
4. Schnaper, H.W. 1995. Balance between matrix synthesis and degradation: a determinant of glomerulosclerosis. Pediatr. Nephrol. 9:104-111.
5. Gaedeke, J., Peters, H., Noble, N.A., and Border, W.A. 2001. Angiotensin II, TGF-β and renal fibrosis. Contrib. Nephrol. 135:153-160.
6. Yu, L., Noble, N., and Border, W. 2002. Therapeutic strategies to halt renal fibrosis. Curr. Opin. Pharmacol. 2:177-181.
7. Loskutoff, D.J., Sawdey, M., and Mimuro, J. 1989. Type 1 plasminogen activator inhibitor. Prog. Hemost. Thromb. 9:87-115.
8. Stetler-Stevenson, W.G. 1996. Dynamics of matrix turnover during pathologic remodeling of the extracellular matrix. Am. J. Pathol. 148:1345-1350.
9. Mignatti, P. 1995. Extracellular matrix remodeling by metalloproteinases and plasminogen activators. Kidney Int. 47:S12-S14.
10. Liotta, L.A., et al. 1981. Effect of plasminogen activator (urokinase), plasmin, and thrombin on glycoprotein and collagenous components of basement membrane. Cancer Res. 41:4629-4636.
11. Mochan, E., and Keler, T. 1984. Plasmin degradation of cartilage proteoglycan. Biochim. Biophys. Acta. 800:312-315.
12. Mackay, A.R., Corbitt, R.H., Hartzler, J.L., and Thorgeirsson, U.P. 1990. Basement membrane type IV collagen degradation: evidence for the involvement of a proteolytic cascade independent of metalloproteinases. Cancer Res. 50:5997-6001.
13. He, C.S., et al. 1989. Tissue cooperation in a proteolytic cascade activating human interstitial collagenase. Proc. Natl. Acad. Sci. U. S. A. 86:2632-2636.
14. Nagase, H., Enghild, J.J., Suzuki, K., and Salvesen, G. 1990. Stepwise activation mechanisms of the precursor of matrix metalloproteinase 3 (stromelysin) by proteinases and (4-aminophenyl)mercuric acetate. Biochemistry. 29:5783-5789.
15. Ramos-DeSimone, N., et al. 1999. Activation of matrix metalloproteinase-9 (MMP-9) via a converging plasmin/stromelysin-1 cascade enhances tumor cell invasion. J. Biol. Chem. 274:13066-13076.
16. Baricos, W.H., Cortez, S.L., El-Dahr, S.S., and Schnaper, H.W. 1995. ECM degradation by cultured human mesangial cells is mediated by a PA/plasmin/MMP-2 cascade. Kidney Int. 47:1039-1047.
17. Romer, J., et al. 1996. Impaired wound healing in mice with a disrupted plasminogen gene. Nat. Med. 2:287-292.
18. Swaisgood, C.M., French, E.L., Noga, C., Simon, R.H., and Ploplis, V.A. 2000. The development of bleomycin-induced pulmonary fibrosis in mice deficient for components of the fibrinolytic system. Am. J. Pathol. 157:177-187.
19. Hattori, N., et al. 2000. Bleomycin-induced pulmonary fibrosis in fibrinogen-null mice. J. Clin. Invest. 106:1341-1350.
20. Eitzman, D.T., et al. 1996. Bleomycin-induced pulmonary fibrosis in transgenic mice that either lack or overexpress the murine plasminogen activator inhibitor-1 gene. J. Clin. Invest. 97:232-237.
21. Barnes, J.L., Mitchell, R.J., and Torres, E.S. 1995. Expression of plasminogen activator-inhibitor-1 (PAI-1) during cellular remodeling in proliferative glomerulonephritis in the rat. J. Histochem. Cytochem. 43:895-905.
22. Keeton, M., Ahn, C., Eguchi, Y., Burlingame, R., and Loskutoff, D.J. 1995. Expression of type 1 plasminogen activator inhibitor in renal tissue in murine lupus nephritis. Kidney Int. 47:148-157.
23. Ma, L.J., et al. 2000. Regression of sclerosis in aging by an angiotensin inhibition-induced decrease in PAI-1. Kidney Int. 88:2425-2436.
24. Shihab, F.S., et al. 1995. Transforming growth factor-beta and matrix protein expression in acute and chronic rejection of human renal allografts. J. Am. Soc. Nephrol. 6:286-294.
25. Yamamoto, T., et al. 1996. Expression of transforming growth factor-beta isoforms in human glomerular diseases. Kidney Int. 49:461-469.
26. Yamamoto, T., et al. 1999. Increased levels of transforming growth factor-beta in HIV-associated nephropathy. Kidney Int. 55:579-592.
27. Paueksakon, P., Revelo, M.P., Ma, L.J., Marcantoni, C., and Fogo, A.B. 2002. Microangiopathic injury and augmented PAI-1 in human diabetic nephropathy. Kidney Int. 61:2142-2148.
28. Lawrence, D.A., et al. 1997. Characterization of the binding of different conformational forms of plasminogen activator inhibitor-1 to vitronectin. Implications for the regulation of pericellular proteolysis. J. Biol. Chem. 272:7676-7680.
29. Tomooka, S., Border, W.A., Marshall, B.C., and Noble, N.A. 1992. Glomerular matrix accumulation is linked to inhibition of the plasmin protease system. Kidney Int. 42:1462-1469.
30. Peters, H., Border, W.A., and Noble, N.A. 1998. Targeting TGF-beta overexpression in renal disease: maximizing the antifibrotic action of angiotensin II blockade. Kidney Int. 54:1570-1580.
31. Eddy, A. 2002. Plasminogen activator inhibitor-1 and the kidney. Am. J. Physiol. Renal Physiol. 283:F209-F220.
32. Olson, J.A., Jr., Shiverick, K.T., Ogilvie, S., Buhi, W.C., and Raizada, M.K. 1991. Angiotensin II induces secretion of plasminogen activator inhibitor I and a tissue metalloprotease inhibitor-related protein from rat brain astrocytes. Proc. Natl. Acad. Sci. U. S. A. 88:1928-1932.
33. Zelezna, B., et al. 1992. Angiotensin-II induction of plasminogen activator inhibitor-1 gene expression in astroglial cells of normotensive and spontaneously hypertensive rat brain. Mol. Endocrinol. 6:2009-2017.
34. Vaughan, D.E., Lazos, S.A., and Tong, K. 1995. Angiotensin II regulates the expression of plasminogen activator inhibitor-1 in cultured endothelial cells. J. Clin. Invest. 95:995-1001.
35. Feener, E.P., Northrup, J.M., Aiello, L.P., and King, G.L. 1995. Angiotensin II induces plasminogen activator inhibitor-1 and-2 expression in vascular endothelial and smooth muscle cells. J. Clin. Invest. 95:1353-1362.
36. Kagami, S., et al. 1997. Dual effects of angiotensin II on the plasminogen/plasmin system in rat mesangial cells. Kidney Int. 51:664-671.
37. Peters, H., Border, W.A., and Noble, N.A. 2000. Angiotensin II blockade and low-protein diet produce additive therapeutic effects in experimental glomerulonephritis. Kidney Int. 57:1493-1501.
38. Peters, H., Border, W.A., and Noble, N.A. 2000. Tandem antifibrotic actions of L-arginine supplementation and low protein diet during the repair phase of experimental glomerulonephritis. Kidney Int. 57:992-1001.
39. Oikawa, T., Freeman, M., Lo, W., Vaughan, D.E., and Fogo, A. 1997. Modulation of plasminogen activator inhibitor-1 in vivo: a new mechanism for the anti-fibrotic effect of renin-angiotensin inhibition. Kidney Int. 51:164-172.
40. Border, W.A., Okuda, S., Languino, L.R., Sporn, M.B., and Ruoslahti, E. 1990. Suppression of experimental glomerulonephritis by antiserum against transforming growth factor beta-1. Nature. 346:371-374.
41. Ziyadeh, F.N., et al. 2000. Long-term prevention of renal insufficiency, excess matrix gene expression, and glomerular mesangial matrix expansion by treatment with monoclonal antitransforming growth factor-beta antibody in db/db diabetic mice. Proc. Natl. Acad. Sci. U. S. A. 97:8015-8020.
42. Miyajima, A., et al. 2000. Antibody transforming growth factor-β ameliorates tubular apoptosis in unilateral ureteral obstruction. Kidney Int. 58:2301-2313.
43. Haraguchi, M., Border, W.A., Huang, Y., and Noble, N.A. 2001. t-PA promotes glomerular plasmin generation and matrix degradation in experimental glomerulonephritis. Kidney Int. 59:2146-2155.
44. Stefansson, S., et al. 2001. Inhibition of angiogenesis in vivo by plasminogen activator inhibitor-1. J. Biol. Chem. 276:8135-8141.
45. Kvassman, J.-O., and Shore, J.D. 1995. Purification of human plasminogen activator inhibitor (PAI-1) from Escherichia coli and separation of its active and latent forms by hydrophobic chromography. Fibrinolysis. 9:215-221.
46. Okuda, S., Languino, L.R., Ruoslahti, E., and Border, W.A. 1990. Elevated expression of transforming growth factor-β and proteoglycan production in experimental glomerulonephritis. J. Clin. Invest. 86:453-462.
47. Yamamoto, T., Noble, N.A., Miller, D.E., and Border, W.A. 1994. Sustained expression of TGF-β1 underlies development of progressive kidney fibrosis. Kidney Int. 45:916-927.
48. Rennard, S.I., Berg, R., Martin, G.R., Foidart, J.M., and Robey, P.G. 1980. Enzyme-linked immunoassay (ELISA) for connective tissue components. Anal. Biochem. 104:205-214.
49. Lark, M.W., Saphos, C.A., Walakovics, L.A., and Moore, V.L. 1990. In vivo activity of human recombinant tissue inhibitor of metalloproteinases (TIMP). Activity agains: human stromelysin in vitro and in the rat pleural cavity. Biochem. Pharmacol. 39:2041-2049.
50. Derynck, R., Jarrett, A., Chen, E.Y., and Goeddel, D.V. 1986. The murine transforming growth factor-β precursor. J. Biol. Chem. 261:4377-4379.
51. Bruzdzinski, C.J., Riordan-Johnson, M., Nordby, E.C., Suter, S.M., and Gelehrter, T.D. 1990. Isolation and characterization of the rat plasminogen activator inhibitor-1 gene. J. Biol. Chem. 265:2078-2084.
52. Schwarzbauer, J.E., Tamkun, J.W., Lemischka, I.R., and Hynes, R.O. 1983. Three different fibronectin mRNAs arise by alternative splicing within the coding region. Cell. 35:421-431.
53. Genovese, C., Rowe, D., and Kream, B. 1984. Construction of DNA sequences complementary to rat alpha 1 and alpha 2 collagen mRNA and their use in studying the regulation of type I collagen synthesis by 1, 25-dihydroxyvitamin D. Biochemistry. 23:6210-6216.
54. Preissner, K.T., and Seiffett, D. 1998. Role of vitronectin and its receptors in haemostasis and vascular remodeling. Thromb. Res. 89:1-21.
55. Preissner, K.T. 1991. Structure and biological role of vitronectin. Annu. Rev. Cell Biol. 7:275-310.
56. Declerck, P.J., et al. 1988. Purification and characterization of a plasminogen activator inhibitor 1 binding protein from human plasma. Identification as a multimeric form of S protein (vitronectin). J. Biol. Chem. 263:15454-15461.
57. Knudsen, B.S., Harpel, P.C., and Nachman, R.L. 1987. Plasminogen activator inhibitor is associated with the extracellular matrix of cultured bovine smooth muscle cells. J. Clin. Invest. 80:1082-1089.
58. Lawrence, D.A., Berkenpas, M.B., Palaniappan, S., and Ginsburg, D. 1994. Localization of vitronectin binding domain in plasminogen activator inhibitor-1. J. Biol. Chem. 269:15223-15228.
59. Mimuro, J., Schleef, R.R., and Loskutoff, D.J. 1987. Extracellular matrix of cultured bovine aortic endothelial cells contains functionally active type I plasminogen activator inhibitor. Blood. 70:721-728.
60. Stefansson, S., et al. 1998. Plasminogen activator inhibitor-1 contains a cryptic high affinity binding site for the low density lipoprotein receptor-related protein. J. Biol. Chem. 273:6358-6366.
61. Stefansson, S., Lawrence, D.A., and Argraves, W.S. 1996. Plasminogen activator inhibitor-1 and vitronectin promote the cellular clearance of thrombin by low density lipoprotein receptor-related proteins 1 and 2. J. Biol. Chem. 271:8215-8220.
62. Argraves, K.M., et al. 1995. The very low density lipoprotein receptor mediates the cellular catabolism of lipoprotein lipase and urokinase-plasminogen activator inhibitor type I complexes. J. Biol. Chem. 270:26550-26557.
63. Herbert, M.-J., and Brady, H.R. 1997. Leukocyte adhesion. In Immunologic renal diseases. E.G. Neilson and W.G. Couser, editors. Lippincott-Raven Publishers. Philadelphia, Pennsylvania, USA. 519-545.
64. Johnson, R.J., Klebanoff, S.J., and Couser, W.G. 1997. Neutrophils. In Immunologic renal diseases. E.G. Neilson and W.G. Couser, editors. Lippincott-Raven Publishers. Philadelphia, Pennsylvania, USA, 519-545.
65. Nikolic-Paterson, D.J., Lan, H.Y., and Atkins, R.C. 1997. Macrophages in immune renal injury. In Immunologic renal diseases. E.G. Neilson and W.G. Couser, editors. Lippincott-Raven Publishers. Philadelphia, Pennsylvania, USA, 575-592.
66. Seiffert, D., Ciambrone, G., Wagner, N.V., Binder, B.R., and Loskutoff, D.J. 1994. The somatomedin B domain of vitronectin. Structural requirements for the binding and stabilization of active type 1 plasminogen activator inhibitor. J. Biol. Chem. 269:2659-2666.
67. Redmond, E.M., et al. 2001. Endothelial cells inhibit flow-induced smooth muscle cell migration: role of plasminogen activator inhibitor-1. Circulation. 103:597-603.
68. Schoppet, M., Chavakis, T., Al-Fakhti, N., Kanse, S.M., and Preissner, K.T. 2002. Molecular interactions and functional interference between vitronectin and transforming growth factor-beta. Lab. Invest. 82:37-46.
69. Deng, G., Curriden, S.A., Wang, S., Rosenberg, S., and Leskutoff D.J. 1996. Is plasminogen activator-inhibitor-1 the molecular switch that governs urokinase receptor-mediated cell adhesion and release? J. Cell Biol. 134:1563-1571.